Fisetin was shown to inhibit phosphorylation of MEK1/2 and ERK1/2 in the MAPK signaling pathway activation pathway and inhibit NFκB in signaling to reduce melanoma A375 cell invasion and metastasis. This evidence concerns the gene MAPK3 and melanoma.